Table 1.
Changes in UUI episodes per week by dose adjustment in the TC-treatment group and the OXY- treatment group (FAS)
| Trospium chloride | Oxybutynin | |||||
|---|---|---|---|---|---|---|
| Time point | No Dose Adjustment | Dose Adjustment | Difference between subgroups | No Dose Adjustment | Dose Adjustment | Difference between subgroups |
| Entrance visit (baseline) | ||||||
| N | 546 | 240 | 575 | 192 | ||
| Mean ± SD | 20.1 ± 17.6 | 22.2 ± 19.58 | 18.6 ± 16.37 | 20.8 ± 18.41 | ||
| Median | 14.0 | 15.0 | 14.0 | 13.0 | ||
| Range | 0.0 - 107.0 | 4.0 - 99.0 | 0.0 - 120.0 | 0.0 - 90.0 | ||
| Intermediate visit | ||||||
| N | 531 | 241 | 561 | 193 | ||
| Mean ± SD | 7.9 ± 11.97 | 12.2 ± 16.4 | 6.5 ± 10.32 | 13.4 ± 17.68 | ||
| Median | 3.0 | 6.0 | 3.0 | 6.0 | ||
| Range | 0.0 - 67.0 | 0.0 - 112.0 | 0.0 - 109.0 | 0.0 - 83.0 | ||
| Final visit | ||||||
| N | 502 | 226 | 534 | 181 | ||
| Mean ± SD | 5.4 ± 10.42 | 7.8 ± 12.49 | 4.4 ± 9.28 | 6.9 ± 13.42 | ||
| Median | 1.0 | 3.0 | 0.0 | 1.0 | ||
| Range | 0.0 - 64.0 | 0.0 - 65.0 | 0.0 - 80.0 | 0.0 - 100.0 | ||
| Change from baseline to final visit | ||||||
| N | 508 | 228 | 537 | 182 | ||
| Mean ± SD | -14.96 ± 15.063 | -14.40 ± 16.346 | -14.29 ± 15.673 | -13.56 ± 15.982 | ||
| Median | -11.00 | -10.58 | -10.00 | -9.00 | ||
| Range | -107.0 - 28.0 | -96.0 - 22.0 | -105.0 - 63.0 | -88.0 - 50.0 | ||
| Hodges-Lehmann estimate | -1.00 | -1.00 | ||||
| 95% CI (non-parametric) | [-2.00; 0.00] | [-2.00; 1.00] | ||||
| P-value | 0.248989 | 0.349402 | ||||
Note: P-values are obtained from the generalised Wilcoxon Rank sum test without stratification for centre.